Alkem Looks To Biosimilars With Enzene’s Teriparatide In India

Rival To Eli Lilly’s Forteo Will Help Alkem Move Into Biosimilars

With the approval in India of its Enzene subsidiary’s version of teriparatide, Alkem is setting its sights on the biosimilars market.

India_Testing
Alkem’s Enzene has had its teriparatide approved in India • Source: Shutterstock

Alkem Laboratories says it is aiming to replicate its success in small-molecule generics with biosimilars, after announcing the approval in India of a rival to Eli Lilly’s Forteo (teriparatide) osteoporosis treatment. The approval came through Alkem’s Enzene Biosciences subsidiary.

Announcing the marketing authorization obtained from the Drug Controller General of India for teriparatide, Alkem said that “according to company...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.